<DOC>
	<DOCNO>NCT02514772</DOCNO>
	<brief_summary>The study objective identify potential safety risk transition US-licensed Rituxan® EU-approved MabThera® GP2013 ( propose biosimilar product ) compare continuous treatment originator product term general safety immunogenicity .</brief_summary>
	<brief_title>GP2013 Treatment Patients With Active Rheumatoid Arthritis , Previously Treated With Rituxan® MabThera®</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Diagnosis RA accord ACR 2010 criterion Completed one full treatment course either Rituxan® MabThera® Eligible treatment course Rituxan® MabThera® Currently treat methotrexate RA functional status class IV ( ACR 1991 revise criterion ) Systemic manifestation RA Positive serology hepatitis B hepatitis C infection Active systemic infection History cancer Known severely immunocompromised state Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>